South San Francisco, United States
HI-Bio, a clinical-stage biotech company, has made a notable impact in the realm of biotechnology since its founding in 2021. The company's focus on delivering targeted therapies for patients with immune-mediated diseases aligns with its mission to innovate in the Biotechnology, Health and Wellness, and Life Sciences industries.
Recently, HI-Bio garnered attention with its acquisition by Biogen on 01 May 2024. This significant step involved a $1.15 billion acquisition investment from Biogen Idec New Ventures, reflecting confidence in the startup's promising pipeline and strategic alignment with Biogen's existing portfolio.
Operating from its headquarters in the United States, HI-Bio's integration into Biogen marks a pivotal moment, promising to accelerate the development and delivery of innovative treatments. This strategic acquisition underscores the robust potential and impactful contributions of HI-Bio to the biotechnology field.
